Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
71,793.72
(
-1.76%
)
News Focus
News Focus
Post# of 257390
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: mcbio post# 133219

Tuesday, 01/17/2012 8:16:12 PM

Tuesday, January 17, 2012 8:16:12 PM

Post# of 257390
ARRY - MEK162 ASCO GI abstract

[Thanks to Patrick for providing this to me.]

http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=88653

In particular, in this Phase 1b trial in biliary tract cancer patients, of 26 patients available for response, there was 1 CR, 1 PR, and 11 SD (greater than or equal to 6 weeks). Keep in mind this is single-agent MEK162 treatment. Curious to hear any feedback from the board on this early data.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today